On December 16, 2021, the U.S. Food and Drug Administration (FDA) announced modifications to the mifepristone REMS were warranted to reduce burden on patient access and the healthcare delivery system and to ensure the benefits of the product outweigh the risks.
Click below for answers to frequently asked questions on this update.